4,619 Shares in Merck & Co., Inc. $MRK Acquired by Ceera Investments LLC

Ceera Investments LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,619 shares of the company’s stock, valued at approximately $556,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $25,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $26,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC raised its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Merck & Co., Inc. Stock Down 0.1%

MRK stock opened at $127.47 on Friday. The firm has a market cap of $314.83 billion, a PE ratio of 35.91, a PEG ratio of 4.40 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm’s 50 day moving average price is $120.11 and its 200-day moving average price is $116.94. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 3.17 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Wall Street Analyst Weigh In

MRK has been the topic of a number of research reports. Bank of America raised their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. BMO Capital Markets boosted their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. CICC Research started coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price objective on the stock. Finally, UBS Group upped their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $133.94.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.